Biotech head leaves chair of working group

May 15, 1998

The crisis at British Biotech, the Oxford company accused of failing to tell the stock market of worrying developments with its drugs development programme, has led to chief executive Keith McCullagh giving up his chairmanship of the government's working group on financing high-technology firms. He is to step down "due to current work pressures on his time", but he remains a group member. Peter Willliams, chairman of Oxford Instruments, will succeed him.

Please login or register to read this article

Register to continue

Get a month's unlimited access to THE content online. Just register and complete your career summary.

Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:

  • Sign up for the editor's highlights
  • Receive World University Rankings news first
  • Get job alerts, shortlist jobs and save job searches
  • Participate in reader discussions and post comments
Register

Have your say

Log in or register to post comments